Incomplete response to therapy in intermediate- and high-risk thyroid cancer

被引:2
|
作者
Alzahrani, Ali S. [1 ,2 ]
Mukhtar, Noha [1 ,2 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh, Saudi Arabia
关键词
Thyroid cancer; Differentiated thyroid cancer; Risk stratification; Recurrence; DISTANT METASTASES; PROGNOSTIC VALUE; STAGING SYSTEM; PAPILLARY; CARCINOMA; AGE; SURVIVAL; RECURRENCE; CLASSIFICATION; ASSOCIATION;
D O I
10.1007/s12020-022-03187-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The American Thyroid Association (ATA) risk stratification system predicts risk of recurrence of differentiated thyroid cancer (DTC). Although the majority of patients achieve an excellent response, patients with intermediate- or high-risk DTC are at a significant risk of developing incomplete responses. We undertook this work to understand the factors associated with development of biochemically or structurally incomplete response in these two risk subgroups of DTC. Patients and methods We retrospectively reviewed 287 consecutive patients with intermediate- (213 patients) or high-risk (74 patients) DTC. All patients underwent total thyroidectomy with (223 patients) or without (64 patients) lymph node dissection and 94% of them received at least one dose of I-131ablation/therapy. Univariate and multivariate analysis and Kaplan Meier analysis were used to compare patients who achieved an excellent response with those who continued to have biochemically or structurally incomplete responses. Results In univariate and multivariate analyses, age (P 0.002, Odds ratio 4.8, 95% CI: 1.8-12.9), tumor size (P 0.027, Odds ratio 1.30, 95% CI: 1.03-1.64) and distant metastases (P < 0.0001, Odds ratio 44.6, 95% CI: 10.7-184.5) were significantly associated with the risk of developing biochemically or structurally incomplete statuses. Patients >= 55 years, tumors > 2.5 cm and presence of distant metastasis were associated with higher risk of incomplete response and death from DTC. However, when this analysis was performed on intermediate and high-risk groups separately, only age was consistently associated with risk of biochemically or structurally incomplete response in either and both groups. Conclusion Age is a strong predictor of biochemically and structurally incomplete responses in patients with intermediate and high-risk DTC.
引用
收藏
页码:531 / 542
页数:12
相关论文
共 50 条
  • [1] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Ali S. Alzahrani
    Noha Mukhtar
    [J]. Endocrine, 2022, 78 : 531 - 542
  • [2] Focal therapy in intermediate- and high-risk prostate cancer
    Huebner, Nicolai A.
    Korn, Stephan
    Rajwa, Pawel
    Shariat, Shahrokh F.
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (04) : 247 - 250
  • [3] Focal therapy in intermediate- and high-risk prostate cancer
    Nicolai A. Huebner
    Stephan Korn
    Pawel Rajwa
    Shahrokh F. Shariat
    [J]. memo - Magazine of European Medical Oncology, 2023, 16 : 247 - 250
  • [4] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Abe, Koichiro
    Ishizaki, Umiko
    Ono, Toshihiro
    Horiuchi, Kiyomi
    Kanaya, Kazuko
    Sakai, Shuji
    Okamoto, Takahiro
    [J]. ANNALS OF NUCLEAR MEDICINE, 2020, 34 (02) : 144 - 151
  • [5] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Koichiro Abe
    Umiko Ishizaki
    Toshihiro Ono
    Kiyomi Horiuchi
    Kazuko Kanaya
    Shuji Sakai
    Takahiro Okamoto
    [J]. Annals of Nuclear Medicine, 2020, 34 : 144 - 151
  • [6] Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
    Yu, Feng
    Li, Xue
    Ji, Yanhui
    Tan, Jian
    Zhang, Guizhi
    Wang, Peng
    He, Yajing
    Wang, Renfei
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [7] Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma
    Kim, Mijin
    Han, Minkyu
    Jeon, Min Ji
    Kim, Won Gu
    Kim, In Joo
    Ryu, Jin-Sook
    Min, Won Bae
    Shong, Young Kee
    Kim, Tae Yong
    Kim, Bo Hyun
    [J]. CLINICAL ENDOCRINOLOGY, 2019, 91 (03) : 449 - 455
  • [8] Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    Raben, David
    Lucia, Scott
    Glode, Michael
    Crawford, E. David
    Kavanagh, Brian
    Raben, Adam
    Ayres, Jennifer
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (09): : 1105 - 1110
  • [9] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    [J]. UROLOGE, 2016, 55 (03): : 318 - +
  • [10] APPLICABILITY ANALYSIS OF FOCAL THERAPY TO INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Matsuoka, Yoh
    Numao, Noboru
    Saito, Kazutaka
    Tanaka, Hiroshi
    Inoue, Masaharu
    Ito, Masaya
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Fujii, Yasuhisa
    Kihara, Kazunori
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E195 - E195